Lineage Cell Therapeutics Inc. (LCTX) last month volatility was 7.61%: Don’t Ignore this Blaring Warning Signal


Witnessing the stock’s movement on the chart, on November 23, 2022, Lineage Cell Therapeutics Inc. (AMEX: LCTX) remained unchanged at $1.47. During the day, the stock rose to $1.51 and sunk to $1.42 before settling in for the price of $1.47 at the close. Taking a more long-term approach, LCTX posted a 52-week range of $1.02-$2.71.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.


The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded -6.00%. Meanwhile, its Annual Earning per share during the time was -22.60%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -90.00%. This publicly-traded company’s shares outstanding now amounts to $169.79 million, simultaneously with a float of $162.41 million. The organization now has a market capitalization sitting at $251.63 million. At the time of writing, stock’s 50-day Moving Average stood at $1.2298, while the 200-day Moving Average is $1.3686.

Lineage Cell Therapeutics Inc. (LCTX) Ownership Facts and Figures

Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Lineage Cell Therapeutics Inc.’s current insider ownership accounts for 0.10%, in contrast to 38.20% institutional ownership. According to the most recent insider trade that took place on Mar 31, this organization’s President and CEO bought 6,400 shares at the rate of 1.53, making the entire transaction reach 9,792 in total value, affecting insider ownership by 97,787. Preceding that transaction, on Mar 28, Company’s Director bought 35,000 for 1.63, making the whole transaction’s value amount to 57,050. This particular insider is now the holder of 35,000 in total.

Lineage Cell Therapeutics Inc. (LCTX) Earnings and Revenue Records

As on 6/29/2022, Multinational firm has announced its last quarter scores, in which it reported -$0.04 earnings per share (EPS) for the period topping the consensus outlook (set at -$0.04) by $0. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.

Lineage Cell Therapeutics Inc.’s EPS decrease for this current 12-month fiscal period is -90.00% and is forecasted to reach -0.16 in the upcoming year.

Lineage Cell Therapeutics Inc. (AMEX: LCTX) Trading Performance Indicators

Let’s observe the current performance indicators for Lineage Cell Therapeutics Inc. (LCTX). It’s Quick Ratio in the last reported quarter now stands at 3.00. The Stock has managed to achieve an average true range (ATR) of 0.09. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 17.97. Similarly, its price to free cash flow for trailing twelve months is now 86.77.

In the same vein, LCTX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.29, a figure that is expected to reach -0.04 in the next quarter, and analysts are predicting that it will be -0.16 at the market close of one year from today.

Technical Analysis of Lineage Cell Therapeutics Inc. (LCTX)

Going through the that latest performance of [Lineage Cell Therapeutics Inc., LCTX]. Its last 5-days volume of 0.63 million was inferior to the volume of 0.65 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 76.47% While, its Average True Range was 0.0985.


Please enter your comment!
Please enter your name here